Some S&P/ASX 200 Index (ASX: XJO) shares have delivered truly extraordinary returns over the past 12 months. Among the standout performers are Sunrise Energy Metals Ltd (ASX: SRL) and 4DMedical Ltd (ASX: 4DX).
At the time of writing, Sunrise Energy shares have surged an astonishing 2,316% to $17.64, while 4DMedical shares have rocketed 1,715% to $4.72.
To put that into perspective, a $10,000 investment in Sunrise Energy a year ago would now be worth approximately $231,600. The same investment in 4DMedical would have grown to roughly $171,500.
After such incredible gains, investors may be asking a simple question: can these rocketing ASX 200 shares keep climbing?
Sunrise Energy: rich scandium resources
Sunrise Energy has emerged as one of the market’s hottest mining stories thanks to its exposure to scandium, one of the world’s rarest and potentially most valuable strategic metals.
Scandium is prized for its ability to enhance aluminium alloys, making them stronger, lighter, and more resistant to heat and corrosion. These characteristics make the metal highly attractive for aerospace, defence, fuel cells, and advanced semiconductor applications.
Australia hosts some of the world’s richest scandium resources, and New South Wales is widely regarded as the only region where scandium could potentially be mined as a primary commodity at scale. That gives the ASX 200 share a unique position in an emerging market with very few credible suppliers.
Investor interest accelerated earlier this year after Beijing imposed export controls on scandium and several other rare earth elements. The move heightened concerns about supply security and increased attention on alternative Western sources.
The challenge for investors is that analyst coverage on the ASX 200 share remains extremely limited. According to TradingView data, only one broker currently covers Sunrise Energy.
The good news is that the broker maintains a strong buy recommendation and a $20.00 price target. Based on the current share price, that implies upside of around 13%.
4DMedical: intersection of healthcare and AI
4DMedical develops advanced respiratory imaging technology that helps clinicians assess lung function in ways traditional imaging methods cannot. Using proprietary software and artificial intelligence, the company generates detailed functional images of the lungs, positioning itself at the intersection of healthcare technology and AI.
Investors have been encouraged by several growth initiatives.
A major recent development was the acquisition of Austrian AI imaging company Contextflow. The deal provides an immediate foothold in Europe, adds lung cancer screening capabilities, and expands the company’s addressable market by an estimated 50%.
Meanwhile, management of the ASX 200 share recently launched its CLEAR clinical program targeting acute pulmonary embolism. The company believes this could help unlock a US market opportunity worth around US$3 billion.
Of course, risks remain. The company is still in growth mode, adoption rates remain critical, and analyst coverage is sparse.
TradingView data shows analysts are divided on the ASX 200 share. Of the three analysts covering the stock, one rates it a buy, one a hold, and one a sell.
The consensus price target sits at $4.97, implying upside of around 5%. The most bullish broker, Bell Potter, sees 27% upside, while Ord Minnett has a $3.00 target, suggesting a downside of roughly 36%.
The post Up 1,700% and more, what’s next for these ASX 200 shares? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Sunrise Energy Metals Ltd right now?
Before you buy Sunrise Energy Metals Ltd shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Sunrise Energy Metals Ltd wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 16 June 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- 5 things to watch on the ASX 200 on Tuesday
- Here are the top 10 ASX 200 shares today
- ASX 200 stuck in the red as investors wait for US lead
- Growthpoint Properties Australia matches FY26 guidance with 18.4c distribution
- Centuria Capital Group launches $300m equity raising for AI Factory and real estate expansion
Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.